Reimbursement Codes: ECG AI’s Path to Recurring Revenue

The entire game for healthcare AI investing changes the moment an algorithm stops being a cool tech demo and starts generating actual revenue. You can see this happen when a company gets regulatory clearance that lines up with an established way to get paid. If you’re an investor trying to figure out if a company’s funding is built to last, you have to see two things: published clinical outcomes and signed payer contracts.

Clearance and Reimbursement

It’s rare, but when a healthcare AI company gets FDA clearance and CPT reimbursement codes at the same time, it’s a powerful combination. That’s the inflection point where a deployed algorithm switches from a one-time software sale that drains a hospital’s budget to a recurring revenue stream. Anumana is the textbook example here, becoming the first ECG AI program to have both FDA clearance and CPT codes in hand Anumana official announcement of FDA clearance and CPT codes. This solves the single biggest problem in selling new tech to hospitals: getting through the budget approval process.

For investors, Anumana’s “reimbursement first” strategy is a blaring signal that the company has a clear route to market and won’t just burn cash. Without a billing pathway, even AI tools with strong clinical validation get stuck in pilot purgatory because hospitals can’t find consistent money to pay for them. The simple ability to bill for the work an ECG AI does rips this barrier away, which is why we’re seeing adoption in cardiology pick up speed.

How a Billing Pathway Drives Adoption and Defines TAM

Having CPT codes for an ECG AI completely changes the nature of demand. Instead of a sales team begging a hospital to find new, unbudgeted money for their solution, the clinic can just recover the cost through its normal billing operations. The whole conversation shifts from a painful capital expenditure fight to a simple discussion about clinical utility and reimbursement. The total addressable market (TAM) for this niche, which is pegged at US$1.1 Billion in 2025 and projected to hit US$2.7 Billion by 2032, is basically defined by how many ECG workflows can actually bill for this kind of AI analysis.

Across the entire healthcare AI space, very few companies manage to pull this off early on, so the ones that do really stand out to investors. The capacity to turn a clinical analysis into a repeatable payment using a recognized billing code is probably the strongest predictor of a company’s long-term financial health. It’s what venture capital firms in this space are looking for when they try to separate real businesses from science projects.

The Mayo Clinic Genesis and Strategic Intent

Anumana’s backstory also explains its smart positioning. The company wasn’t started in a garage. It was a spin-out from research at the Mayo Clinic Mayo Clinic announcement of Anumana spin-out. That kind of institutional backing gives you immediate clinical credibility and serious research muscle. From day one, their recorded strategy was “reimbursement first,” which shows they understood the brutal realities of commercializing healthcare tech. This is a sharp contrast to the many AI health companies that get regulatory clearance and then spend years fighting a losing battle to get paid.

When you have a top-tier research institution like Mayo Clinic developing your ECG AI algorithms for things like low EF, pulmonary hypertension, and cardiac amyloidosis, and you pair that with a clear strategy for getting reimbursed, you become a company that shows up on every digital health funding rounds tracker. This integrated approach, from bench research to billing, is exactly what savvy healthcare AI investors want to see more of.

The CMS Coverage Decision as a Market Signal

When we talk about the size of the healthcare AI market, the CMS coverage decision for cardiac analysis is a huge market signal. What does that decision really do? It tells investors exactly which algorithm companies can actually get paid for their work. A thumbs-up from the Centers for Medicare & Medicaid Services (CMS) is the ultimate validation of an AI tool’s clinical and economic case, making it an instantly better bet for investment. Anumana, being the first ECG AI company to get both clearance and reimbursement codes, created the blueprint for others to follow.

Top VCs in healthcare AI are watching this stuff like hawks. The companies that are set up for durable funding are the ones that can show a clear line to reimbursement that’s backed by solid clinical data and regulatory green lights. This intense focus on reimbursement-backed algorithm businesses is the defining trend for venture capital in this space for 2026 and well beyond.